The second study to complete was the breast cancer trial (NCT01151046; Figure 7a), in which patients with hormone receptor-positive, HER2-negative metastatic breast cancer were randomized 1:1 to receive either exemestane in combination with seribantumab, or exemestane in combination with placebo. Here, NR4A1 is linked to breast carcinoma.